KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Share-based Compensation: 2018-2025

Historic Share-based Compensation for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to $2.8 million.

  • Aquestive Therapeutics' Share-based Compensation rose 76.09% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year increase of 53.50%. This contributed to the annual value of $7.1 million for FY2024, which is 164.00% up from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' Share-based Compensation is $2.8 million, which was up 47.40% from $1.9 million recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year Share-based Compensation high stood at $2.8 million for Q3 2025, and its period low was $344,000 during Q1 2023.
  • For the 3-year period, Aquestive Therapeutics' Share-based Compensation averaged around $1.5 million, with its median value being $1.6 million (2024).
  • Per our database at Business Quant, Aquestive Therapeutics' Share-based Compensation slumped by 71.84% in 2022 and then surged by 359.30% in 2024.
  • Quarterly analysis of 5 years shows Aquestive Therapeutics' Share-based Compensation stood at $1.7 million in 2021, then slumped by 57.78% to $714,000 in 2022, then skyrocketed by 31.65% to $940,000 in 2023, then surged by 155.64% to $2.4 million in 2024, then surged by 76.09% to $2.8 million in 2025.
  • Its last three reported values are $2.8 million in Q3 2025, $1.9 million for Q2 2025, and $1.6 million during Q1 2025.